Picture loading failed.

Anti-SLC34A2 therapeutic antibody (Pre-made Lifastuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lifastuzumab vedotin, also known as DNIB0600A and RG-7599, is a novel antibody-drug conjugate being developed by Genentech/Roche, in clinical trials. The investigational drug is being compared to pegylated liposomal doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-311-1mg 1mg Inquiry
GMP-Bios-ab-311-10mg 10mg Inquiry
GMP-Bios-ab-311-100mg 100mg Inquiry
GMP-Bios-ab-311-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-SLC34A2 therapeutic antibody (Pre-made Lifastuzumab biosimilar,Whole mAb ADC)
INN Name Lifastuzumab
TargetSLC34A2
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesGenentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedFallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer
Development Techna